



CaroGen's CARG-2020 Preclinical Data on Ovarian Cancer Immunotherapy to be Presented Orally at the Society of Gynecologic Oncology Annual Meeting

Farmington, CT, November 8, 2022 – CaroGen Corporation (<https://carogencorp.com>), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that new preclinical data about the mechanism of action of CaroGen's novel ovarian cancer immunotherapy, CARG-2020, will be presented in a plenary session of the Society of Gynecologic Oncology meeting on Women's Cancer in Tampa, Florida on March 25-28, 2023 (<https://www.sgo.org/events/annual-meeting>). This oral presentation will be made by Prof. Gil Mor, MD, PhD and Prof. Ayesha Alvero, MD, M.Sc., both of Wayne State University School of Medicine.

“CARG-2020, working through specific immune mechanisms of action, has displayed impressive preclinical effectiveness in treating and preventing tumor recurrence, and has also shown significant survival advantage in animal models of ovarian cancer. We believe that the modulation of both innate and adaptive immune responses by CARG-2020 in preclinical models has the potential to become an important new therapeutic alternative for ovarian cancer patients where existing immune therapies have failed,” said Dr. Mor, the John M. Malone Jr. MD, Endowed Chair and Scientific Director of The C.S. Mott Center for Human Growth and Development at Wayne State University, and formerly of Yale School of Medicine where the collaboration was initiated.

CARG-2020, CaroGen's lead clinical candidate, belongs to a new class of genetically modified oncolytic viral therapies, of which Imlygic® (Amgen) is the only therapy approved by the FDA. Besides its oncolytic activity, CARG-2020 incorporates three immune-modulating payloads to prevent tumorigenesis and overcome immune exhaustion, instead of one for Imlygic®. “The proof-of-concept safety and efficacy studies have been completed for CARG-2020 in multiple solid tumor models including colorectal, ovarian, liver, melanoma, and breast cancer. By engaging three immune signaling pathways (IL-12, IL-17RA and suppression of PD-L1), CARG-2020 immunotherapy results in elimination of primary tumors and prevention of tumor recurrence”, said Bijan Almassian, PhD, CaroGen's Co-founder and CEO.

About CaroGen Corporation

CaroGen is building a pipeline of immunotherapies using its patented **AVIDIO** immunotherapy platform in collaboration with scientists at elite academic institutions including Yale University, University of Connecticut, Brown University, Albany Medical College and Wayne State University. Based in Farmington, CT, CaroGen possesses a broad and growing patent portfolio with issued composition of matter and method of use patents and has been awarded over \$10 million in NIH and Department of Defense grants.

Contact information:

Bijan Almassian, Ph.D.

President and CEO

balmassian@carogencorp.com

Tel: 203-815-5782